摘要
肿瘤细胞多药耐药是临床肿瘤化疗失败最常见和最难克服的问题之一,亦是复发、转移的主要原因.因此肿瘤耐药逆转成为当今肿瘤研究中的热点之一.近年来,基于对肿瘤病灶部位的分子水平的研究,发现了许多新的治疗靶点,如ErbB-2,为开发新型的高效低毒的新药从而逆转肿瘤多药耐药提供了可能.
One of the most common yet difficult to resolve problems in clinical tumor chemotherapy is multidrug resistance （MDR）. It is also the major factor leading to tumor recurrence, even to metastasis. Hence, investigations into multidrug resistance of tumors have recently become very common. New therapeutic targets have been discovered based on molecular research into tumor lesions as ErbB-2. These should provide possibilities for reversing tumor MDR by developing new types of antitumor drugs that have higher performance and are less harmful than existing treatments.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第18期2042-2045,共4页
World Chinese Journal of Digestology
